New hope for Tough-to-Treat colorectal cancer?

NCT ID NCT05990543

Ongoing Disease control Sponsor: Korea University Anam Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests a new drug called nelmastobart combined with the chemotherapy capecitabine in people with metastatic colorectal cancer that no longer responds to standard treatments. About 59 adults will receive the combination to see if it is safe and can slow cancer growth. The goal is to find a better option for patients with limited choices.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nelmastobart and capecitabine
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced colorectal cancer who have run out of standard chemotherapy choices.
What could go wrong: This is an early-phase trial with only 59 participants, so results may not apply to all patients. The drug combination may cause side effects or fail to improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal adenocarcinoma colorectal cancer colorectal neoplasm Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT OR METASTATIC COLORECTAL CANCER

Contacts and locations

Locations

Korea University Medical Center 73, Goryeodae-ro, Seongbuk-gu

Seoul, Seoul, 02841, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.